These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 19438397

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K.
    Clin Infect Dis; 2006 Jul 15; 43(2):253-5. PubMed ID: 16779754
    [Abstract] [Full Text] [Related]

  • 23. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, Liverpool TDM Database, UK CHIC Study.
    Antivir Ther; 2008 Jul 15; 13(5):675-85. PubMed ID: 18771051
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.
    AIDS; 2007 Apr 23; 21(7):813-23. PubMed ID: 17415036
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM, ANRS 12146-CARINEMO Study Group.
    Antimicrob Agents Chemother; 2014 Jun 23; 58(6):3182-90. PubMed ID: 24663014
    [Abstract] [Full Text] [Related]

  • 31. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.
    Antivir Ther; 2007 Jun 23; 12(4):515-21. PubMed ID: 17668560
    [Abstract] [Full Text] [Related]

  • 32. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.
    HIV Med; 2005 Sep 23; 6(5):353-9. PubMed ID: 16156884
    [Abstract] [Full Text] [Related]

  • 33. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
    Deng SC, Chen MY, Hsieh SM, Sheng WH, Hsiao CF, Hung CC, Chang SC.
    J Microbiol Immunol Infect; 2003 Mar 23; 36(1):10-4. PubMed ID: 12741726
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team.
    N Engl J Med; 2001 Aug 09; 345(6):398-407. PubMed ID: 11496850
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec 09; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 38. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM.
    J Infect Dis; 2005 Feb 01; 191(3):324-32. PubMed ID: 15633090
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R.
    J Antimicrob Chemother; 2006 Nov 01; 58(5):1017-23. PubMed ID: 16956905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.